Scientists are advancing a promising new strategy against antibiotic-resistant infections by harnessing bacteriophages, viruses that specifically target and kill harmful bacteria. An international team has released the first coordinated guidelines for personalized phage therapy, offering a roadmap for safely translating this experimental treatment into clinical practice. The guidance addresses key issues including patient selection, phage preparation and regulatory oversight, aiming to standardize an approach that has until now varied widely between research groups and hospitals. Early findings are encouraging: one study reported clinical improvement in 77 percent of patients treated with the therapy, while targeted bacteria disappeared in 61 percent of cases. The results suggest phage therapy could become a valuable complement to conventional antibiotics, particularly for infections where existing drugs have failed.
Antibiotic resistance is among the most pressing threats to global public health, with the World Health Organization warning that common infections risk becoming untreatable as existing drugs lose effectiveness. Phage therapy, first explored a century ago, has seen renewed interest as resistance grows, though large-scale clinical trials remain limited and questions persist over dosing, bacterial resistance to phages and manufacturing standards. The new guidelines are intended to give researchers and clinicians a common framework while regulatory bodies weigh how to oversee personalized treatments. Experts caution that the early results, while encouraging, come from small studies and require confirmation in larger controlled trials. The international team says the next phase will focus on expanding clinical testing and building the evidence base needed for broader adoption.
Independent reporting synthesized from primary wires and global correspondents.